

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant: EFENDIC, Suad

Group Art Unit: 1646

Serial No.: 10/811,646

Examiner:
CHANDRA, Gyan

Application Date: March 29, 2004

Conf No.: 3074

For: USE OF GLP-1 OR ANALOGS IN TREATMENT OF
MYOCARDIAL INFARCTION

Docket No.: X-10822B

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Under the guidelines of 37 C.F.R. 1.97, Applicant submits a copy of each of the documents listed on the attached Form PTO-1449 (modified) for consideration by the Examiner.

This modified 1449 form and Information Disclosure Statement is being filed to make certain information related to Interference No. 105,457 as well as other information of record in the present Application.

Since this Statement is being filed before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. § 1.114, Applicant submits that no fee is due. The Office is authorized to charge any fees which may be required by this or any other related paper, or credit any overpayment to Deposit Account No. 05-0840.

Applicant requests consideration of this information.

Respectfully submitted,

/Mark J. Stewart/
Mark J. Stewart
Attorney for Applicant
Registration No. 43,936
Phone: 317-276-0280

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288
March 22, 2007